ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2016
Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 190 citations in OpenAlex.
- Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.The Journal of clinical endocrinology and metabolism · 2024Trial
- The natural history of osteogenesis imperfecta: a systematic review.Bone reports · 2026Review
- Surgical Treatment of Tibial Tubercle Fractures in Osteogenesis Imperfecta: A Restrospective Case Series.Journal of the Pediatric Orthopaedic Society of North America · 2026Article
- What's New in Osteogenesis Imperfecta.Journal of the Pediatric Orthopaedic Society of North America · 2026Review
- Clinical and Genetic Characterization of Osteogenesis Imperfecta in Japanese Patients: Outcomes of Sequential Bisphosphonate Therapy.Calcified tissue international · 2026Article
- Dose-, duration- and age-dependent effects of zoledronic acid on bone structure and mechanical properties in growing rice rats.Frontiers in endocrinology · 2026Article
- Genetic landscape and phenotypic spectrum of osteogenesis imperfecta in the Kazakhstani pediatric population.Scientific reports · 2025Article
- Optimizing bone health with bisphosphonate therapies in pediatric osteogenesis imperfecta: a network meta-analysis of randomized trials.Archives of osteoporosis · 2025Article
- A novel SGMS2 mutation associated with high bone mass; description of an affected family with recurrent fragility fractures.Bone reports · 2025Article
- Osteogenesis imperfecta in Peruvian children: Phenotypic and therapeutic insights from a pediatric hospital.Intractable & rare diseases research · 2024Article
- Article
- Ophthalmological screening guidelines for individuals with Osteogenesis Imperfecta: a scoping review.Orphanet journal of rare diseases · 2024Article
- Low muscle density in children with osteogenesis imperfecta using opportunistic low-dose chest CT: a case-control study.BMC musculoskeletal disorders · 2024Article
- Cranio-cervical abnormalities in moderate-to-severe osteogenesis imperfecta - Genotypic and phenotypic determinants.Orthodontics & craniofacial research · 2024Article
- Article
- The vitamin D status in a Chinese osteogenesis imperfecta population and its correlation with bone metabolic markers and bone density.Frontiers in nutrition · 2024Article
- Analysis of miRNAs inPharmaceuticals (Basel, Switzerland) · 2023Article
- Standardized growth charts for children with osteogenesis imperfecta.Pediatric research · 2023Article
- Transition from Pediatric to Adult Health Care in Osteogenesis Imperfecta.Current osteoporosis reports · 2023Review
- The patient-related factors in revision procedures on tibia of patients with osteogenesis imperfecta treated with the Peter-Williams nail.Journal of orthopaedic surgery and research · 2023Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteogenesis imperfecta (OI) is the most prevalent heritable bone fragility disorder in children. It has been known for three decades that the majority of individuals with OI have mutations in COL1A1 or COL1A2, the two genes coding for collagen type I alpha chains, but in the past 10 years defects in at least 17 other genes have been linked to OI. Almost all individuals with a typical OI phenotype have a mutation in one of the currently known genes. Regarding medical treatment, intravenous bisphosphonate therapy is the most widely used medical approach. This has a marked effect on vertebra in growing children and can lead to vertebral reshaping after compression fractures, but there is little effect of bisphosphonate therapy on the development of scoliosis. Bisphosphonate treatment decreases long-bone fracture rates, but such fractures are still frequent. Newer medications with anti-resorptive and bone anabolic action are being investigated in an attempt to improve on the efficacy of bisphosphonates but the safety and efficacy of these new approaches in children with OI is not yet established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.